SG11201909552VA - Combination therapy for prostate cancer - Google Patents
Combination therapy for prostate cancerInfo
- Publication number
- SG11201909552VA SG11201909552VA SG11201909552VA SG11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- johnson
- effective amount
- therapeutically effective
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909552VA true SG11201909552VA (en) | 2019-11-28 |
Family
ID=62067858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909552V SG11201909552VA (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20180296574A1 (es) |
| EP (3) | EP4176878A1 (es) |
| JP (3) | JP7141408B2 (es) |
| KR (1) | KR20190134718A (es) |
| CN (1) | CN110753545A (es) |
| AU (2) | AU2018251594A1 (es) |
| BR (1) | BR112019021466A2 (es) |
| CA (1) | CA3059562A1 (es) |
| CL (1) | CL2019002871A1 (es) |
| CO (1) | CO2019011591A2 (es) |
| CR (1) | CR20190467A (es) |
| DK (1) | DK3609497T3 (es) |
| DO (1) | DOP2019000264A (es) |
| EA (1) | EA201992430A1 (es) |
| ES (1) | ES2931052T3 (es) |
| HR (1) | HRP20221327T1 (es) |
| HU (1) | HUE060460T2 (es) |
| JO (1) | JOP20190244A1 (es) |
| LT (1) | LT3609497T (es) |
| MA (1) | MA48728B1 (es) |
| MD (1) | MD3609497T2 (es) |
| MX (2) | MX2019012296A (es) |
| NI (1) | NI201900105A (es) |
| PE (1) | PE20200444A1 (es) |
| PH (1) | PH12019502317A1 (es) |
| PL (1) | PL3609497T3 (es) |
| PT (1) | PT3609497T (es) |
| RS (1) | RS63832B1 (es) |
| SG (1) | SG11201909552VA (es) |
| WO (1) | WO2018191141A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109640991A (zh) | 2016-07-29 | 2019-04-16 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN113546037A (zh) * | 2020-04-20 | 2021-10-26 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| MX2022014003A (es) * | 2020-05-08 | 2022-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib. |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| JP7320903B2 (ja) | 2021-12-15 | 2023-08-04 | 湖南慧▲澤▼生物医▲薬▼科技有限公司 | アビラテロン酢酸エステルを含む組成物及び使用 |
| WO2023194525A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101528308A (zh) * | 2006-08-25 | 2009-09-09 | 库伽尔生物科技公司 | 治疗癌症的方法和组合物 |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
| RU2495035C2 (ru) | 2008-01-08 | 2013-10-10 | Мерк Шарп Энд Домэ Лтд | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0244A patent/JOP20190244A1/ar unknown
-
2018
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en active Application Filing
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Application Discontinuation
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro unknown
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 BR BR112019021466-6A patent/BR112019021466A2/pt active Search and Examination
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909552VA (en) | Combination therapy for prostate cancer | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900361RA (en) | Methods of treating prostate cancer |